Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of ibrutinib with optional nivolumab in selected rollover participants
MOH_2018-07-16_002521Phase 3Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibrutinib and nivolumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), mantle cell lymphoma (MCL), follicular lymphoma (FL) and 3 more (2 arms), sponsored by Actelion Pharmaceuticals Ltd. Started Apr 2015; status: active, not recruiting.
02
Drugs
ibrutinibnivolumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)mantle cell lymphoma (MCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on MOH_2018-07-16_002521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-16_002521.